Sequential Treatment of Hepatocellular Carcinoma by Transarterial Chemoembolization and Local Ablation or External Radiation

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04813861

Acronym

CELPerCutCHC

Enrollment

Registered

2021-03-24

Start date

2010-01-04

Completion date

2021-03-31

Last updated

2021-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Keywords

Hepatocellular Carcinoma, Transarterial Chemoembolization, Stereotactic body radiotherapy, Radiofrequency Ablation, Microwave Ablation

Brief summary

Hepatocellular carcinoma (HCC) can present itself in many forms (size, number of lesions) for the treatment of which a therapeutic panel can be elaborated and layered. If a curative treatment cannot be considered in case of an HCC classified in an intermediate stage, a Transcatheter Arterial Chemoembolization (TACE) can be proposed. In case of a partial response or the treatment of some lesions of a multifocal HCC, a combined treatment by stereotaxic radiotherapy (CK), radiofrequency ablation (RFA) or microwave ablation (MWA) may be initiated in accordance with a decision of the multidisciplinary consultation meeting. The aim of this study was to evaluate the clinical outcome of HCC receiving MWA, RFA or CK after downstaging with TACE.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* a HCC treated by TACE followed by RFA, MWA and/or CK * from 01/2010 to 12/2020 * treated by Nancy Regional University Hospital (TACE, RFA, MWA) and Institut de Cancérologie de Lorraine (CK)

Exclusion criteria

* Combined treatment over one year following the last TACE * No baseline, in between or after combined treatment imaging * Lesion appeared after TACE treatment

Design outcomes

Primary

Measure	Time frame	Description
Lesion Response	4-6 weeks after BWA or RFA or 3-6 months after CK	Lesion response after combined treatment

Secondary

Measure	Time frame	Description
Delayed Lesion Response	1 year after BWA, RFA or CK	Lesion response a year after combined treatment

Countries

France

Outcome results